|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| NEEFLrNyFTDkAAs SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 10887913 |
| Available spectra: 1 CST |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Disease tissue studied: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Treatments: | |
| References | |
|---|---|
|
Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info |
|
|
Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info |
|
|
Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info |
|
|
Possemato A (2010) CST Curation Set: 9704; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
|
Jørgensen C, et al. (2009) Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326, 1502-9
20007894 Curated Info |
|
|
MS Claus Jorgensen dataset-Toronto
Curated Info |